Cellgenic Set to Open New Stem Cells Center in Belgium through Partnership with Churchill Aesthetic Center
The subsidiary of the Global Stem Cells Group seeks to meet the growing demand for patients seeking stem cells treatments across the globe.
MIAMI LAKES, Florida— Cellgenic, a subsidiary of the Global Stem Cells Group (GSCG), has announced that it has signed an agreement that will bring regenerative medical treatments to more patients across Europe with the opening of a new stem cells treatment center in Belgium.
The agreement, signed between the GSCG and Dr. Samy Joheir, owner of Churchill Aesthetic Center (https://www.churchill-aesthetic-center.be/), expands the GSCG’s mission of expanding access to regenerative medicine globally. The agreement opens the center’s doors to patients seeking stem cells treatment options and to physicians across Europe and the Middle East seeking educational opportunities regarding how to incorporate regenerative medicine into their practices. The center is located at 141 Winston Churchill Avenue, B-1180 in Brussels.
The Brussels center will also serve as the GSCG’s head offices and will help the group better serve patients and doctors across Europe and the Middle East.
To new center will officially open on September 30, 2019. In conjunction with the center’s opening, the GSCG and Dr. Joheir will welcome three patients from the Middle East seeking treatments offered by the center. These patients were previously treated in the US prior to the institution of stricter FDA stem cells regulations. The Belgium center will provide these patients with treatment options closer to home, alleviating emotional, financial, and physical stressors in receiving treatment, similar to the group’s current facilities in Cancun that provide critical stem cells treatment to patients traveling from the US.
With the opening of the center, the GSCG also aims to provide more accessible educational facilities and options for physicians in the region looking to receive training in regenerative medicine. The training is in alignment with the services currently offered at the GSCG’s other facilities, such as those located in Cancun for physicians across the Americas.
Over the past few years, the GSCG has sought to achieve its mission in helping to alleviate human suffering by opening stem cells centers across the globe to meet growing patient demands. All of the group’s centers are all currently located outside of the US due to current FDA regulations restricting regenerative medicine products and protocols.
“The Global Stem Cells Group is pleased to be able to reach more patients seeking relief through regenerative medicine with the opening of our Belgian center,” said Benito Novas, CEO of the Global Stem Cells Group. “This expansion will help alleviate travel and financial barriers some European and Middle Eastern patients face in receiving the care they need, now providing them access to a facility closer to home. We are committed to opening up additional treatment centers for both physicians and patients across the globe who may be limited by their local regulations in accessing critical stem cells therapies. Through our facilities, patients looking for relief from regenerative diseases will receive top-notch care in state-of-the-art facilities.”
To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Global Stem Cells Group Set to Conduct Clinical Trials in Miami
MIAMI LAKES, Florida—The Global Stem Cells Group (GSCG), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, announced its participation in a new clinical trial in Miami. The trial is sponsored by InGeneron, Inc. and will provide researchers the opportunity to compare two treatment options in patients with partial-thickness rotator cuff tears (PTRCTs). Patient groups will be injected either with a single injection of adipose-derived regenerative cells (ADRCs) or a single corticosteroid injection to examine the efficacy of both treatment protocols.
The study is a prospective, double-blinded, randomized, active-controlled, multi-site, pivotal safety and superior effectiveness study in patients with symptomatic partial-thickness rotator cuff tears. Researchers will compare a single ADRC injection generated with the Transpose® RT system into the supraspinatus tendon and surrounding area to standard-of-care (SOC) corticosteroid injection into the subacromial bursa.
Up to 20 U.S. centers will be initiated to enroll in the study. Two hundred and forty six subjects will be assigned to two randomization arms: an adipose-derived regenerative cell (ADRC) injection arm (ADRC treatment arm) and the SOC corticosteroid injection arm (active control arm). All subjects will be randomly assigned to the ADRC treatment or active control arms in a 2:1 ratio.
The GSCG clinical trial is registered with the US Food and Drug Administration (FDA) and will adhere to all FDA safety protocols. The GSCG will help recruit patients for the study. The goal of the trial is to demonstrate the safety and efficacy of stem cells treatments in helping to treat patients suffering from degenerative diseases and injuries such as PTRCTs.
“The Global Stem Cells Group is committed to helping people across the globe find relief from debilitating diseases and is pleased to serve as a leader in cutting-edge research in the stem cells field,” said Benito Novas, CEO of the Global Stem Cells Group. “This clinical trial will hopefully help us achieve these goals by demonstrating the safety and efficacy of regenerative medicine treatments to physicians, patients, and regulatory bodies so that more patients are able to have access to these treatment protocols and find relief.”
To learn more about the clinical trial, visit https://clinicaltrials.gov/ct2/show/NCT03752827. To learn more about the Global Stem Cells Group and its latest efforts, visit http://www.stemcellsgroup.com/.
- Published in Press Releases
Lans Holdings Secures Extension to Complete Acquisition of Global Stem Cells Group
MIAMI, FL, Sept. 11, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Lans Holdings Inc. is pleased to announce that it has successfully secured a 180-day extension to complete the acquisition of 100% of Global Stem Cells Group Inc (GSCG).
On Friday September 6, 2019, trading in the company’s stock was suspended due to a missed communication regarding the pending delinquent annual filings. Company management has had several discussions with the SEC and has determined that an old address is the cause for the missing paperwork. The Company has agreed to enter into a settlement with the SEC, which will result in the deregistering of the Company’s shares. Company management had been working with its auditors, accounting staff and outside consultants for the past few months to bring the Company’s filings current when the Company learned of the revocation. The Company intends to now file a form 10 to reregister its common shares with the SEC and to locate a market maker to sponsor the Company in a 211 filing to reinstate trading of the Company’s shares.
“We regret the concern this put on the market, and especially the delay in communication of these events, as we had to ensure that we had accurately secured all of the necessary agreements to successfully recover from this disruption,” said Dave Christensen, CEO of Lans Holdings. “We have been working diligently on catching up all records and we are looking forward to quickly submitting a Form 10, and then closing the acquisition.”
This press release should be read in conjunction with all other filings on www.sec.gov
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
- Published in Press Releases
Global Stem Cells Group Set to Sponsor Cancun Medical Congress
Global Stem Cells’ group affiliate Adimarket set to launch new products during the international event.
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, will host a two-day medical congress in Cancun, Mexico. The 7 Congreso Internacional de Terapias Avanzadas en Medicina will take place on December 7-8, 2019 and will feature speakers from various countries, including the United States, Argentina, Mexico, and Colombia.
Congress organizers expect over 250 Mexican doctors will attend the event, which will feature a variety of experts in the field of regenerative medicine and cutting-edge products in the industry that are designed to help treat patients suffering from degenerative diseases.
Adimarket, the largest online regenerative medicine store and a subsidiary of the Global Stem Cells Group, will be on hand to launch its newest allogeneic stem cells products during the event. These heterologous compounds were developed exclusively for a LATAM market, striking a balance between a high-quality treatment option and an affordable price. Products currently offered by Adimarket in this category include exosomes, cord blood derived stem cells, and stem cells derived from amniotic fluid.
All of Adimarket’s products are designed to help provide safe and effective treatment options to doctors treating patients suffering from degenerative diseases.
To learn more about Adimarket and all of its regenerative medicine solutions, visit https://www.adimarket.net/. To learn more about ISSCA and all of their upcoming and past events, visit https://issca.us/.
- Published in Press Releases
Global Stem Cells Group’s Benito Novas Announces Agreement with Clinica Planas
The ongoing partnership will offer certification in regenerative medicine for European-based medical practitioners .
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has signed an agreement with European-based Clinica Planas to offer a stem cells certification training program. The first event will be held in Barcelona on October 18-19, 2019.
“The Global Stem Cells Group is pleased to partner with Clinica Planas to offer this important certification in cell therapies,” said Benito Novas, Vice President of the Global Stem Cells Group. “This partnership will continue our mission to help provide knowledge of regenerative medicine practices and treatment options to physicians across the globe.”
Clinica Planas has two locations in Spain—Barcelona and Madrid—and is known as one of the most prestigious medical centers in Europe. In this new deal, Clinical Planas will partner with the Global Stem Cells Group to help train European-based physicians in the regenerative medicine industry’s best practices and most up-to-date knowledge.
The inaugural certification workshop will be held on October 11-12 in Barcelona, with additional certification opportunities to be offered on an ongoing basis in the future. During the two-day event, physicians will receive insight on 22 proprietary treatment protocols to treat degenerative diseases, acquire skills to be able to offer alternative treatment options to patients who have yet to try regenerative medicine as an option, and join an exclusive network of doctors at the forefront of medical science.
“Our goal is to help physicians looking for new treatment options for their patients suffering from degenerative diseases gain the necessary skills to be able to offer regenerative treatments as an option to alleviate their patients’ suffering,” Novas noted.
To learn more about the October 2019 certification event in Barcelona, visit http://cursocelulasmadre.com/entrenamiento-en-barcelona/.
To learn more about Clinica Planas, visit https://www.clinicaplanas.com/en. To learn more about ISSCA and all of their upcoming and past events, visit https://issca.us/.
- Published in Press Releases
Lans Holdings Enters into Binding LOI to Acquire Global Stem Cells Group
MIAMI LAKES, FL, May 30, 2019-Global Stem Cells Group Inc. (GSCG) is pleased to announce that it has entered into a binding letter of intent to sell 100% to Lans Holdings Inc. (OTCPink: LAHO)
GSCG operates in the global stem cell market which is forecasted by Transparency Market Research to reach $270 billion dollars by 2025 of which roughly 40% or $100 billion will be derived from outside of North America and growing at a 13.8% compounded annual growth rate.
GSCG specializes in leading-edge stem cell research, patient application and physician training. The company licenses its name and intellectual property to physicians around the world and supplies them with necessary equipment and medical supplies to perform stem cell treatments. The company currently has one of the largest member clinic networks in the world spanning over 25 countries.
“We are very pleased to have entered into this binding LOI with Global Stem Cells Group,” said Dave Christensen, CEO of Lans Holdings Inc. “This transaction represents a significant opportunity for our company to enter the explosive field of Stem Cell technology with a proven and seasoned team and I look forward to working closely with GSCG to execute on their growth plans.”
“We are excited to join forces with Lans Holdings,” said Benito Novas, President and CEO of Global Stem Cells Group. “This union will allow us to have access to the capital markets to further fuel our growth as the global stem cells market enters into an accelerated expansion phase.”
- Published in Press Releases